Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Dose-finding and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HTMC0435 With Temozolomide in Patients With Small Cell Lung Cancer

NCT05728619 is registered in ClinicalTrials.gov with Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT05728619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05728619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Dose-finding and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HTMC0435 With Temozolomide in Patients With Small Cell Lung Cancer
Lead sponsor
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 3, 2023
Completion date
October 31, 2024
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent extensive stage small cell lung carcinoma